# Meihua Biotech (600873): The performance in the first half of the year was in line with expectations, and the industry position continued to consolidate and improve

> Meihua Biotech reported first-half 2025 revenue of 12.28 billion yuan, down 2.87% year on year, while net income rose 19.96% to 1.768 billion yuan. Growth was driven by a sharp rise in the volume and price of 70% lysine and lower raw material costs, while feed-grade amino acid revenue grew 3.4%.

- Date: 2025-08-18 · published 2025-08-18T12:00:00.000Z
- Category: market · region China · magnitude low
- Page: https://feedsoft.ai/events/23647-meihua-biotech-600873-the-performance-in-the-first-half-of-the-year-was-in-line
- Commodities: [Lysine](https://feedsoft.ai/c/LYSINE.md)

## Why it matters

Higher lysine prices and falling input costs show tighter amino acid margins for feed producers and suggest firmer lysine pricing, which raises feed formulation costs.

## Read by commodity

- LYSINE: bullish ▲

## Sources

- news.futunn.com: https://news.futunn.com/en/post/60846038/meihua-biological-600873-first-half-performance-meets-expectations-industry-position

---
Data from Feedsoft AI (https://feedsoft.ai/). For information only; not investment advice.